pharmaphorum August 2, 2022
“First, do no harm”; is an ethical axiom at the heart of medical research; physicians worldwide pledge to uphold the oath to serve patients. Clinical trials offer a practical example of how this value can be realised in drug development, reinforcing the importance of understanding and evaluating the safety and efficacy of new therapies in a controlled environment (clinical trials) before they reach patients at large.
However, within this clinical trial landscape there remains a significant ethical and scientific gap. For many years, clinical trials in oncology have almost exclusively catered to specific demographics when selecting trial subjects – namely White participants – a stark contrast to the reality of the diverse racial and ethnic populations that make up society...
Today's Sponsors
Today's Sponsor